Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?

Vassilakopoulos Theodoros

首页> 外文期刊>The lancet oncology >Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?

【24h】

Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?

机译：复发或难治性古典霍奇金淋巴瘤：哪种免疫疗法，何时？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The lancet oncology》 |2021年第4期|共3页
作者
Vassilakopoulos Theodoros;
展开▼
作者单位

Natl &

Kapodistrian Univ Athens Dept Haematol &

Bone Marrow Transplantat Laikon Gen Hosp Athens;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin [J] . Zhi-Gang Cao, Hong-Wei Zhou, Chao-Jin Peng, 癌症（英文版） . 2013,第009期
2. Early relapse and refractory disease remain risk factors in the anthracycline and autologous transplant era for patients with relapsed/refractory classical Hodgkin lymphoma: A single centre intention-to-treat analysis [J] . GreavesP., WilsonA., MatthewsJ., British Journal of Haematology . 2012,第2期

机译：复发/难治性经典霍奇金淋巴瘤患者的早期复发和难治性疾病仍是蒽环类和自体移植时代的危险因素：单中心意向性治疗分析
3. Primary Refractory and Relapsed Classical Hodgkin Lymphoma - Significance of Differential CD15 Expression in Hodgkin-Reed-Sternberg Cells [J] . Daniel Benharroch, Shai Pilosof, Jacob Gopas, Journal of Cancer . 2012,第16期

机译：原发性难治性和复发性经典霍奇金淋巴瘤-霍奇金-里德-斯特恩伯格细胞中差异CD15表达的意义。
4. Retreatment with brentuximab vedotin in patients with relapsed/refractory classical Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: a multicenter retrospective study [J] . Leukemia and lymphoma . 2020,第1a2期

机译：与Brentuximab Vedotin进行后退，患者复发/难治经典霍奇金淋巴瘤或全身轴承性大型细胞淋巴瘤：多中心回顾性研究
5. Autotransplant Approach with Rituximab in High Grade Primary Refractory or Progressive Non Hodgkin's Lymphomas (NHL). 2nd Report [C] . D. Vallisa, A. Lazzaro, R. Berte, European Haematology Association . 2002

机译：用Rituximab在高级初级耐火或渐进非霍奇金淋巴瘤（NHL）中的rituximab的自同毒性方法。第二次报告
6. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
7. Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group [O] . Stephen Daw, Dirk Hasenclever, Maurizio Mascarin, 2020

机译：针对儿童和年轻人的初次复发和难治性经典霍奇金淋巴瘤的风险和反应适应性治疗指南。 EuroNet儿科霍奇金淋巴瘤小组的建议
8. Risk and Response Adapted Treatment Guidelines for Managing First Relapsed and Refractory Classical Hodgkin Lymphoma in Children and Young People. Recommendations from the EuroNet Pediatric Hodgkin Lymphoma Group [O] . Stephen Daw, Dirk Hasenclever, Maurizio Mascarin, 2020

机译：风险和反应适应了管理儿童和年轻人的首次复发和难治性古典霍奇金淋巴瘤的治疗准则。欧罗尼特儿科霍奇金淋巴瘤组的建议
9. Immune Response Genotypes and Risk of Young Adult Hodgkin Lymphoma [R] . Cozen, W., Cortessis, V., Conti, D., 2008

机译：免疫应答基因型与年轻成人霍奇金淋巴瘤的风险

Relapsed or refractory classical Hodgkin lymphoma: which immunotherapy, and when?

著录项

相似文献

相关主题

期刊订阅